Page last updated: 2024-08-21

pyrazines and Central Nervous System Diseases

pyrazines has been researched along with Central Nervous System Diseases in 4 studies

Research

Studies (4)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	3 (75.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	1 (25.00)	2.80

Authors

Authors	Studies
Lim, KJC; Tam, CS	1
Benson, L; Einzig, AI; Grove, WR; Lathia, CD; Roca, J; Sklarin, NT; Thomas, S; Wiernik, PH	1
Abbruzzese, JL; Ajani, J; Diaz-Canton, E; Grove, W; Meyers, C; Patt, Y; Pazdur, R	1
Bowling, MK; Donehower, RC; Grochow, LB; Long, GS; Noe, DA; Rowinsky, EK; Sartorius, SE	1

Reviews

1 review(s) available for pyrazines and Central Nervous System Diseases

Article	Year
Zanubrutinib for the treatment of Waldenström Macroglobulinemia. Expert review of hematology, 2020, Volume: 13, Issue:12 Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Antineoplastic Agents; Atrial Fibrillation; Benzamides; Central Nervous System Diseases; Clinical Trials as Topic; Febrile Neutropenia; Gastrointestinal Diseases; Gene Expression Regulation, Neoplastic; Humans; Multicenter Studies as Topic; Myeloid Differentiation Factor 88; Neoplasm Proteins; NF-kappa B; Piperidines; Progression-Free Survival; Protein Kinase Inhibitors; Pyrazines; Pyrazoles; Pyrimidines; Quality of Life; Receptors, CXCR4; Recurrence; Salvage Therapy; Signal Transduction; Treatment Outcome; Waldenstrom Macroglobulinemia	2020

Article

Year

Zanubrutinib for the treatment of Waldenström Macroglobulinemia.

Expert review of hematology, 2020, Volume: 13, Issue:12

Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Antineoplastic Agents; Atrial Fibrillation; Benzamides; Central Nervous System Diseases; Clinical Trials as Topic; Febrile Neutropenia; Gastrointestinal Diseases; Gene Expression Regulation, Neoplastic; Humans; Multicenter Studies as Topic; Myeloid Differentiation Factor 88; Neoplasm Proteins; NF-kappa B; Piperidines; Progression-Free Survival; Protein Kinase Inhibitors; Pyrazines; Pyrazoles; Pyrimidines; Quality of Life; Receptors, CXCR4; Recurrence; Salvage Therapy; Signal Transduction; Treatment Outcome; Waldenstrom Macroglobulinemia

2020

Trials

3 trial(s) available for pyrazines and Central Nervous System Diseases

Article	Year
A phase I trial and pharmacokinetic evaluation of CI-980 in patients with advanced solid tumors. Investigational new drugs, 1997, Volume: 15, Issue:3 Topics: Adult; Aged; Antineoplastic Agents; Area Under Curve; Biological Availability; Carbamates; Central Nervous System Diseases; Drug Tolerance; Female; Humans; Male; Metabolic Clearance Rate; Middle Aged; Nausea; Neoplasms; Neutropenia; Pyrazines; Pyridines	1997
Phase II trial of intravenous CI-980 (NSC 370147) in patients with metastatic colorectal carcinoma. Model for prospective evaluation of neurotoxicity. American journal of clinical oncology, 1997, Volume: 20, Issue:6 Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Carbamates; Central Nervous System Diseases; Colorectal Neoplasms; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Male; Middle Aged; Prospective Studies; Pyrazines; Pyridines	1997
Phase I and pharmacological study of CI-980, a novel synthetic antimicrotubule agent. Clinical cancer research : an official journal of the American Association for Cancer Research, 1997, Volume: 3, Issue:3 Topics: Adult; Aged; Antineoplastic Agents; Carbamates; Central Nervous System Diseases; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Infusions, Intravenous; Male; Metabolic Clearance Rate; Middle Aged; Neoplasms; Neutropenia; Pyrazines; Pyridines; Thrombocytopenia	1997